Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
SLNO Soleno Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: SLNO
Price (delayed)
$76.26
Market cap
$3.84B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.65
Enterprise value
$3.81B
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company's lead candidate, Diazoxide Choline Controlled-Release (DCCR) tablets, a once-daily oral tablet
Highlights
Soleno Therapeutics's quick ratio has surged by 66% YoY and by 19% QoQ
SLNO's equity has surged by 62% year-on-year but it is down by 5% since the previous quarter
The EPS has dropped by 126% year-on-year and by 6% since the previous quarter
Soleno Therapeutics's net income has decreased by 13% from the previous quarter
Key stats
What are the main financial stats of SLNO
Market
Valuations
Earnings
Shares outstanding
50.39M
Market cap
$3.84B
Enterprise value
$3.81B
Price to earnings (P/E)
N/A
Price to book (P/B)
15.06
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$204.13M
Net income
-$198.23M
EBIT
-$196.63M
EBITDA
-$194.06M
Free cash flow
-$89.53M
Per share
Balance sheet
Liquidity
EPS
-$4.65
EPS diluted
-$4.65
Free cash flow per share
-$1.94
Book value per share
$5.06
Revenue per share
$0
TBVPS
$6.75
Total assets
$318.09M
Total liabilities
$85.83M
Debt
$52.79M
Equity
$232.26M
Working capital
$293.18M
Debt to equity
0.23
Current ratio
19.64
Quick ratio
18.43
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-63.4%
Return on equity
-77.5%
Return on invested capital
-78.9%
Return on capital employed
-65%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
SLNO stock price
How has the Soleno Therapeutics stock price performed over time
Intraday
2.14%
1 week
1.65%
1 month
29.17%
1 year
64.85%
YTD
69.66%
QTD
6.73%
Financial performance
How have Soleno Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$204.13M
Net income
-$198.23M
Gross margin
N/A
Net margin
N/A
Soleno Therapeutics's net income has decreased by 13% from the previous quarter
The operating income has contracted by 11% from the previous quarter
Price vs fundamentals
How does SLNO's price correlate with its fundamentals
Growth
What is Soleno Therapeutics's growth rate over time
Valuation
What is Soleno Therapeutics stock price valuation
P/E
N/A
P/B
15.06
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has dropped by 126% year-on-year and by 6% since the previous quarter
The price to book (P/B) is 75% higher than the last 4 quarters average of 8.6
SLNO's equity has surged by 62% year-on-year but it is down by 5% since the previous quarter
Efficiency
How efficient is Soleno Therapeutics business performance
The return on invested capital has surged by 76% year-on-year and by 6% since the previous quarter
The company's return on assets fell by 35% YoY
The ROE has contracted by 25% YoY and by 2.9% from the previous quarter
Dividends
What is SLNO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for SLNO.
Financial health
How did Soleno Therapeutics financials performed over time
SLNO's total assets has soared by 88% year-on-year but it is down by 3.9% since the previous quarter
SLNO's current ratio has soared by 75% YoY and by 25% QoQ
SLNO's debt is 77% smaller than its equity
SLNO's equity has surged by 62% year-on-year but it is down by 5% since the previous quarter
The company's debt to equity rose by 4.5% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.